To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

January 19, 2021

Expanded Use of Innovative Brain Tumor Treatment Exemplified in GT Medical Technologies’ 2020 GammaTile® Therapy

To all our Supporters, Friends and Colleagues and especially to the Patients and Caregivers we serve and to the Healthcare Workers who tirelessly work on behalf of all of us!

First of all, I want to take this opportunity to mark the passing of a momentous year and wish everyone a much better 2021. It certainly has been quite the ride!

I want to start off 2021 by sharing exciting news from Corporate Partner GT Medical who offer a truly groundbreaking treatment for those undergoing surgery for their brain tumor in the form of safe and effective surgically targeted radiation delivered right to the tumor site.

I personally believe that GammaTile Therapy is a game changer for patients with malignant brain tumors and would like to personally congratulate those centers achieving ELITE status in 2020:

  • Memorial Sloan Kettering Cancer Center
  • University of Minnesota M Health Fairview
  • HonorHealth Scottsdale Osborn Medical Center
  • NorthShore University HealthSystem
  • Mayfield Brain & Spine

Read the full press release HERE.

I am looking for these numbers to increase exponentially in 2021. Because it means that far more patients with brain tumors will start off their journey with radiation that’s targeted to their tumor and is much less debilitating. This represents a double win and I can’t wait for the day when GammaTile Therapy becomes standard practice.

Happy New Year and cheers!

Dellann Elliott Mydland
President & CEO
EndBrainCancer Initiative (EBCI)/Chris Elliott Fund

“There is currently no other device that is able to achieve what GammaTile has for our brain tumor patients. It is the first device of its kind, and its ability to deliver safe and effective surgically targeted radiation is groundbreaking in the neuro-oncology community. We’re proud to be included in this year’s group of GammaTile Therapy ELITE Member institutions.”
-Dr. Julian Bailes
Chair of the Department of Neurosurgery, NorthShore University Health System


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram